Alpha memo: resveratrol exercise context boundary

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Tighten the novelty signal to a bounded contrast: e.g., 'at lower dose and in healthier aged men, resveratrol may blunt one oxidised LDL-related vascular benefit of training, while a 2021 pilot found higher doses feasible in functionally limited older adults — boundaries across dose, population, and endpoint remain unresolved.'
2. Add an explicit dose/population/endpoint non-equivalence caveat in the one-sentence alpha so readers cannot infer a direct contradiction between Receipt 1 and Receipt 2.
3. Verify or hedge the ~45% statistic given the truncated source bundle excerpt; either cite the specific metric (e.g., 'an oxidised LDL-related measure' without invoking the 45% if unverified) or note that the figure is taken from author description of their own effect.
4. Add a falsifier that names the dose (250 vs 500/1000 mg) and population as moderators to be tested, not just 'dose, duration, baseline training status.'

Major issues

• The 'Why this is surprising' framing implicitly equates different doses (500-1000 mg/day in Receipt 1 vs 250 mg/day in Receipt 2) and different durations (12 vs 8 weeks) and different populations (functional limitations vs healthy inactive aged men) as if they directly contradict, when the dose-response, population, and endpoint families all differ. The novelty signal needs to be tighter on what is actually being contrasted.
• Receipt 1's safe/feasible inference is stated as if settled, but Receipt 1 itself is a pilot (N=60) explicitly not powered for efficacy and with different primary endpoints than Receipt 2. The memo should not lean on Receipt 1 to 'make plausible' the intervention without flagging that feasibility does not establish safety in all conditions or that the two studies measured incompatible outcomes.

Minor issues

• The ~45% figure could be clarified: Receipt 2's excerpt shows 'Exercise training led to a 45' (truncated); the memo should note the source bundle truncates the exact statistic and that the description as a ~45% reduction relative to training+placebo is derived from the manuscript's own phrasing rather than verified text.
• Receipt 2 is from 2013, outside the typical recency window; acceptable given the memo's historical anchor but worth noting the age gap vs Receipt 1 (2021).
• Population descriptors differ ('older adults with functional limitations' vs 'healthy inactive aged men'); memo acknowledges this implicitly but could be more explicit in the one-sentence alpha to prevent a misread of head-to-head generalisability.

Reviewer note

Bounded two-receipt evidence map on resveratrol + exercise. Title and one-sentence alpha correctly anchor on resveratrol + exercise; both receipts match the anchor. The novelty framing is salvageable but currently conflates dose (250 vs 500-1000 mg/day), duration (8 vs 12 weeks), population (healthy inactive aged men vs functionally limited older adults), and outcome family (oxidised LDL-related vascular measure vs safety/feasibility/physical function/muscle endpoints). The 'surprising' framing therefore reads stronger than the receipts support. Sources are real, recent (one in window, one historical but legitimately so), and directly cited; source_grounding holds at 4. The 45% statistic relies on author paraphrase and a truncated bundle excerpt, so the memo should hedge or verify. Limitations and falsifiers are spelled out and useful; add the dose/population non-equivalence as an explicit boundary. Recommend revise.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis